Hos liposomal anthracykliske- resistente patienter var responsraten sammenlignelig med patienter, der aldrig havde fået en proteasehæmmer (55, 6%) og de, der havde fået én mindst 2 måneder inden behandlingen med Paxene (60, 9%).
In liposomal anthracycline-resistant patients, the response rates were comparable for patients who had never received a protease inhibitor (55.6%) and those who received one at least 2 months prior to treatment with Paxene (60.9%).